Vanessa Alves de Medeiros1, Hellen Bandeira de Pontes Santos2, Bárbara Vanessa de Brito Monteiro3, Alexandre Rolim da Paz4, Pollianna Muniz Alves1, Cassiano Francisco Weege Nonaka5,6. 1. Department of Dentistry, State University of Paraíba, Campina Grande, PB, Brazil. 2. Faculty of Nursing and Medicine Nova Esperança, Professional Master in Health Family, João Pessoa, PB, Brazil. 3. Department of Dentistry, Federal University of Campina Grande, Patos, PB, Brazil. 4. Department of Pathology, Federal University of Paraíba, João Pessoa, PB, Brazil. 5. Department of Dentistry, State University of Paraíba, Campina Grande, PB, Brazil. cfwnonaka@gmail.com. 6. Departamento de Odontologia, Programa de Pós-Graduação em Odontologia, Universidade Estadual da Paraíba, Rua Baraúnas, 351, Bairro Universitário, Campina Grande, PB, Brazil. cfwnonaka@gmail.com.
Abstract
PURPOSE: The aim of this study was to evaluate the presence and distribution of multinucleated giant cell (MGC) reactions in 61 cases of OTSCC and to verify the association of this microscopic finding with clinicopathological parameters (gender, age, tumor size/extent, regional lymph node metastasis, distant metastasis, clinical stage, and histopathological grade of malignancy). METHODS: Clinical data were collected from medical records and the histopathological grade of malignancy of OTSCCs was evaluated using the World Health Organization (WHO) grading system. The presence and distribution of MGC reaction in high power fields (HPFs) were evaluated in hematoxylin-eosin-stained histological sections. In all cases containing MGCs, immunohistochemical analysis for CD68 was performed in order to confirm the histiocytic nature of these cells. RESULTS: Twenty-one (34.4%) cases had MGC reactions, with a higher frequency of the focal distribution pattern (57.1%). All MGCs were immunohistochemically positive for CD68. The absence of MGC reaction was significantly associated with regional lymph node metastasis (PR: 2.75; 95% CI 1.05-7.20; p = 0.027), advanced clinical stage (PR: 3.37; 95% CI 1.28-8.85; p = 0.006), and moderately/poorly differentiated tumors (PR: 3.36; 95% CI 1.51-7.48; p = 0.001). No significant associations were observed between the distribution of MGCs and clinicopathological parameters (p > 0.05). CONCLUSION: Taken together, the results of this study suggest that the absence of MGC reaction may represent an indicator of tumor progression in OTSCCs.
PURPOSE: The aim of this study was to evaluate the presence and distribution of multinucleated giant cell (MGC) reactions in 61 cases of OTSCC and to verify the association of this microscopic finding with clinicopathological parameters (gender, age, tumor size/extent, regional lymph node metastasis, distant metastasis, clinical stage, and histopathological grade of malignancy). METHODS: Clinical data were collected from medical records and the histopathological grade of malignancy of OTSCCs was evaluated using the World Health Organization (WHO) grading system. The presence and distribution of MGC reaction in high power fields (HPFs) were evaluated in hematoxylin-eosin-stained histological sections. In all cases containing MGCs, immunohistochemical analysis for CD68 was performed in order to confirm the histiocytic nature of these cells. RESULTS: Twenty-one (34.4%) cases had MGC reactions, with a higher frequency of the focal distribution pattern (57.1%). All MGCs were immunohistochemically positive for CD68. The absence of MGC reaction was significantly associated with regional lymph node metastasis (PR: 2.75; 95% CI 1.05-7.20; p = 0.027), advanced clinical stage (PR: 3.37; 95% CI 1.28-8.85; p = 0.006), and moderately/poorly differentiated tumors (PR: 3.36; 95% CI 1.51-7.48; p = 0.001). No significant associations were observed between the distribution of MGCs and clinicopathological parameters (p > 0.05). CONCLUSION: Taken together, the results of this study suggest that the absence of MGC reaction may represent an indicator of tumor progression in OTSCCs.
Authors: Marisa R Buchakjian; Timothy Ginader; Kendall K Tasche; Nitin A Pagedar; Brian J Smith; Steven M Sperry Journal: Otolaryngol Head Neck Surg Date: 2018-05-08 Impact factor: 3.497
Authors: Laith Mukdad; Thomas E Heineman; Jose Alonso; Karam W Badran; Edward C Kuan; Maie A St John Journal: Laryngoscope Date: 2018-12-21 Impact factor: 3.325
Authors: Kevin D Shield; Jacques Ferlay; Ahmedin Jemal; Rengaswamy Sankaranarayanan; Anil K Chaturvedi; Freddie Bray; Isabelle Soerjomataram Journal: CA Cancer J Clin Date: 2016-10-19 Impact factor: 508.702
Authors: Ahmed A M Essa; Manabu Yamazaki; Satoshi Maruyama; Tatsuya Abé; Hamzah Babkair; Jun Cheng; Takashi Saku Journal: J Oral Pathol Med Date: 2014-06-14 Impact factor: 4.253
Authors: C Rubio; E Munera-Maravilla; I Lodewijk; C Suarez-Cabrera; V Karaivanova; R Ruiz-Palomares; J M Paramio; M Dueñas Journal: Clin Transl Oncol Date: 2018-10-05 Impact factor: 3.405